Skip to Main Content
Jeffrey Orenstein

Jeffrey Orenstein is a counsel in the firm’s Washington, D.C. office. He has over 12 years of experience handling international trade and transportation matters. He specializes in providing strategic counsel in the areas of U.S. sanctions, export controls, customs, maritime, and railroad regulation. He is a trusted advisor for trade-related compliance, investigations, due diligence, training programs, and representation in enforcement actions, including matters before the Office of Foreign Assets Control (OFAC), the Bureau of Industry and Security (BIS), the Directorate of Defense Trade Controls (DDTC), and Customs and Border Protection (CBP).

Jeffrey advises multinational corporations on trade regulations in an array of regulatory contexts, including compliance with the Export Administration Regulations (EAR), the International Traffic in Arms Regulations (ITAR), U.S. sanctions and embargoes, import regulations, free trade agreements, and remedial tariffs and duties implemented by the Department of Commerce, CBP, and the U.S. Trade Representative (USTR). He also routinely counsels corporations on anti-boycott laws, the Foreign Corrupt Practices Act (FCPA), and national security reviews by the Committee on Foreign Investment in the United States (CFIUS) into acquisitions and investments.

  • Tariffs & Trade Issues, International Titanium Association Conference (Oct. 9, 2018).
  • Compliance with U.S. Sanctions against Russia, CLE/CPD Webinar (Aug. 27, 2018).
  • Checking All the Required Boxes, ACI’s ITAR Bootcamp (June 7, 2018).
  • The Trump Tariffs & Their Impact, CLE/CPD Webinar (May 3, 2018).
  • Country of Origin Requirements, 6th Annual Medical Device & Diagnostic Labeling Conference (Apr. 27, 2018).
  • Country of Origin Requirements, 4th Annual Medical Device & Diagnostic Labeling Conference (Apr. 25, 2016).
  • Crude by Rail: Understanding the Amended Regulations for Rail Transport, Webinar (June 3, 2015).
  • Crude Oil Exports, U.S. Energy and Commodities Conference (Sept. 17, 2015).
  • Panel Discussion on Maritime Law, Georgetown Law Center (Nov. 28, 2011).
  • Federal Preemption of State Shipping Regulation, Green Pacific Conference (Sept. 22, 2010).
Additional Thought Leadership Pages
  • Pharma Ruling Broadens Gov't Drug Procurement Options,” Law360, 24 February 2020
  • Sanctions compliance and enforcement – a global update, FINANCIER WORLDWIDE (May 2017).
  • Supply chain risks under US and EU sanctions and export controls, FINANCIER WORLDWIDE (April 2017).
  • VA Now Open To Non-Trade Agreements Act Compliant Drugs, LAW360 (May 3, 2016).
  • Veterans Affairs to Permit Acquisition of Non-TAA-Compliant Drugs, LEXOLOGY (April 22, 2016).
  • U.S. Government Repeals Crude Oil Export Ban, PRATT’S ENERGY LAW REPORT (April 2016).
  • 10 Things To Know About Crude Oil Swap Licenses, LAW360 (October 22 2015).
  • Medical Device Companies Face Increased TAA Scrutiny, LAW360 (March 20, 2015).
  • BIS Explains 'Commingling' and Scope of Crude Oil Export Controls, DOWNSTREAMTODAY (January 13, 2015).
  • Country of Origin’ Compliance: The Top 10 Things Pharmaceutical Companies Need to Know (February 6, 2014).
  • Origin of the Pieces: How to Determine a Pharmaceutical Product’s 'Country of Origin', 43 PUB. L. J 489 (2014).
  • Joseph Almeida: Portrait of a Privateer, Pirate and Plaintiff, Part II, 12 GREEN BAG 2D. 35 (2008).
  • Joseph Almeida: Portrait of a Privateer, Pirate & Plaintiff, Part I, 10 GREEN BAG 2D. 307 (2007).
  • Show Me the Monet: The Suitability of Product Disparagement to Art Experts, 13 GEO. MASON L. REV. 905 (2005).
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel